MedDeviceGuideMedDeviceGuide
Back

How to Support an Opened IVD Reagent’s In-Use Stability Claim

Map opened IVD reagent claims to their handling, time and temperature evidence, using source-bound examples and a practical manufacturer review table.

Ran Chen
Ran Chen
Global MedTech Expert | 10× MedTech Global Access
Published 2026-11-17Last reviewed 2026-11-1713 min read

An IVD reagent can remain within its printed expiry while its opened-use configuration still needs supporting evidence. For a bottle moved between a refrigerator and an analyzer, assess the actual opening event, container, storage conditions, loading sequence and elapsed time. Support the proposed usable period with evidence covering that configuration, and apply every applicable labeled limit, including the original expiry. U.S. reagent labeling requirements connect storage instructions to reliable, meaningful and specific testing. 21 CFR 809.10(a)(5) and (b)(5).

A useful manufacturer review produces one evidence record for each claimed state. Start with unopened storage, opened storage and on-instrument use. Add preparation or reconstitution when the product requires it. The worked tables below extract named public records and identify missing conditions. Their durations belong to the specified products and documents. For a proposed claim, complete the same fields with the product’s own labeling and study reports.

Identify the use condition behind the proposed expiry

Write the proposed instruction in operational terms before choosing a stability study. Identify the reagent or kit component, its container and closure, the event that starts the interval, and the permitted environment. Record whether the clock measures calendar time after first opening, cumulative time loaded, or another explicitly defined exposure. Those questions form an editorial review method for making the claim testable.

Keep separate entries for a reagent bottle, a calibrator bottle, calibration validity, patient-specimen holding and the final reaction’s reading window. Each entry identifies a different object or event. This separation lets the reviewer ask which observations support the exact sentence proposed for the instructions for use. It also gives the labeling team a clear place to record interactions between intervals.

The jurisdiction matters. Health Canada’s IVD labeling guidance, adopted and effective 22 April 2016, addresses storage conditions for unopened, opened, onboard and reconstituted or mixed reagents. It discusses expiry for unopened components and for opened components when their expiry differs. It also asks for directions-for-use issue dates and revision identification. The foreword characterizes the document as an administrative instrument without force of law. These are Canadian guidance statements. Health Canada, sections 2.2.8, 2.2.9 and 2.3.6.

Build the time and environment claim table

Use the following table as an editorial synthesis of reported evidence. “Unspecified” means the cited passage leaves that field open. Resolve it from the current instructions or underlying report before using the row to support a new label. The locator accompanies each numerical entry so another reviewer can reproduce the extraction. The historical HmX rows retain their document date.

Status and product/documentConfigurationInitiating eventClaimed duration or dateStorage or use environmentExposure sequence and shelf ageEvidence locatorUnresolved conditions
Reported • IDS three assays, K253817Unopened shelf lifeStored kit12 months2–8°CReal-time study, three lots, tested at several time points.p. 15Current labeled expiry statement
Reported • IDS assays, K253817On instrumentOpening and loadingSS-A/Ro and SS-A/Ro 60 kDa, 56 days. SS-B/La, 42 days.Instrument temperature unspecifiedOne lot opened and kept onboard, 12 time points. Age unspecified.p. 15Current environmental limits
Reported • IDS assays, K253817Opened, intermittent useOpeningSS-A/Ro and SS-A/Ro 60 kDa, 56 days. SS-B/La, 42 days.2–8°C between usesOne lot, 8 time points. Cartridges removed and refrigerated after each. Age unspecified.p. 15Instrument temperature and schedule
Reported • ISOTON III, HmX guide PN 4237530BB, March 2011Open containerContainer openingPrinted shelf-life dateLaboratory ambientConnected reagent. Tested age unspecified.pp. 1-26–1-27Current instructions and numerical ambient range
Reported • LYSE S III diff, HmX guide PN 4237530BB, March 2011Open containerContainer opening60 daysLaboratory ambientConnected reagent. Tested age unspecified.pp. 1-26–1-27Current instructions and applicable original expiry

Read across each row before comparing durations. A complete time entry alongside an unresolved environmental field remains an incomplete basis for writing a new instruction. In a manufacturer’s review copy, add the exact report revision and the relevant labeling revision together. Maintain a link to the evidence even when the released instructions eventually express the claim in a short sentence.

Read the IDS workflows separately

The IDS decision summary for K253817 describes two separate opened-reagent studies. In the onboard study, one lot of the reagent kit was opened, stored on the IDS system and assessed over 12 time points using one to two negative and five positive serum samples. In the in-use study, one lot was assessed with an open cartridge vial over 8 time points using four positive serum samples, and the cartridges were removed from the system after each time point and stored at 2–8°C. Its onboard passage supplies no numerical instrument temperature. Both workflows support the same durations: 56 days for SS-A/Ro and SS-A/Ro 60 kDa, and 42 days for SS-B/La. K253817, reagent stability, printed p. 15.

Equal durations do not make the two workflows interchangeable. A label that permits only continuous onboard storage rests on the first study, while a label that permits removal and refrigerated return rests on the second. Use the row matching the proposed handling sequence. The same summary also illustrates why method citations need care: its stability section states that the studies followed CLSI EP25, 2nd Ed., while its list of referenced standards names “CLSI EP25-A2.” Record the edition exactly as each document states it, and ask the report owner to resolve any inconsistent label before the evidence table is finalized. K253817, sections on standards and reagent stability, printed pp. 8 and 14–15.

For the opening scenario, ask the report owner to trace each removal, return and reload against the proposed instruction. Record whether a future user can reproduce the studied handling sequence from the label alone. If the instruction permits repeated transfers, request the evidence identifying the allowed frequency and exposure conditions. An unfilled field should generate a specific evidence question with a named report owner.

Keep the refrigerator setpoint and analyzer environment in their own fields. Add the locations where temperature was measured and explain how the recorded values correspond to the reagent’s exposure. This is a proposed review practice. The manufacturer should justify the environmental representation for its particular container, instrument and workflow. A reviewer can then assess whether the proposed wording covers precisely the conditions studied.

Track component life and calibration validity

The Beckman Coulter Total Immunoglobulin E summary in K220178 separates three in-use parameters. Table 9.8.1 reports the following results for pre-stressed kits aged 29 months, against a stated claimed shelf life of 24 months. Its reagent footnote says the reagent stayed onboard throughout the study. K220178, section 9.8 and table 9.8.1.

Reported parameterInitiating event to identifyClaimTested toReported conditionStudy context and locator
IgE reagent open bottleBottle opening28 days29 days2–8°C, onboard throughoutPre-stressed, aged 29 months. K220178, table 9.8.1
IgE calibrator open bottleBottle opening45 days54 days2–8°CSame table and aged-kit context
IgE calibration intervalCalibration14 days15 days2–8°C table conditionSame table. Calibration-cycle footnote applies

Section 9.8 also states the study design behind those rows. The in-use metrics were evaluated at both the start and end of the shelf stability period for kits stored at 2–8°C, including kits exposed to winter and summer post-shipping stress conditions. Three levels of quality control material were tested, and the mean IgE recovery at the last time point had to fall within 10 IU/mL or 10% of the mean Day 0 recovery. The calibration-interval footnote distinguishes a cycle whose Day 15 point uses the Day 0 curve from a cycle recalibrated on Day 15. The 2022 submission cites CLSI EP25-A; preserve that historical edition. Apply the labeled 24-month shelf life together with the opened-use limits when interpreting the aged-kit study. K220178, section 9.8 and table 9.8.1.

In a proposed product record, assign a separate identifier to every component and interval. Then ask which event updates each date in the instructions, instrument interface and laboratory record. Include a field for the original expiry and a field for the applicable opened-use limit. This makes the interaction reviewable when a fresh calibration is performed using an already opened reagent bottle.

For software date handling, consider a product-specific boundary review. Proposed cases could include a bottle opened close to its printed expiry, a reload of the same bottle, replacement with another bottle from the same lot, and a calibration performed late in the opened-use period. Define the expected permitted-use result from approved product instructions before testing the interface. Document the bottle identity and every relevant timestamp so the reviewer can reconstruct the decision.

When open-container stability equals the printed expiry

The March 2011 COULTER HmX Operator’s Training Guide lists ISOTON III diluent open-container stability as “same as shelf life,” meaning the date printed on the container. The same table gives LYSE S III diff lytic reagent a 60-day entry, and the guide states that all reagents should be stored and used at the laboratory’s ambient room temperature. It also tells users to treat each container as if it may have frozen during transport, to confirm complete thawing and to mix by inversion before use. This dated example shows that an opened-container claim can retain the printed expiry. HmX guide PN 4237530BB, pp. 1-26–1-27.

The guide’s reagent-change procedure shows how a date claim reaches the instrument. The operator enters the lot number and either the expiration date or the open-container stability date, as applicable. The date opened changes automatically to the current date when the lot number is entered, and the guide notes that open-container stability is stated on the reagent container when applicable. For a software-tracked claim, the entered date, the opening event and the labeled statement therefore need to agree. HmX guide PN 4237530BB, p. 1-27.

For a proposed same-date claim, request evidence for the intended opened configuration through the applicable expiry. In the review record, identify the handling sequence and the tested age of the opened product. If a software field accepts the printed date, trace that entered value back to the product’s supported claim. This historical example supplies a review question for another product, whose current instructions and supporting reports must establish its own limits.

Request evidence for the proposed workflow

The next table is an editorial evidence-request template. Its fields and suggested scenarios are proposals for manufacturer review. Select and justify the relevant conditions for the product and applicable jurisdiction. Keep requested durations visibly unresolved until the evidence and claim assessment are complete. The purpose is to connect a proposed instruction with observations that actually represent its use.

Status and proposed configurationEvent and time definitionEnvironment to documentExposure and shelf age to justifyEvidence requestedClaim disposition
Evidence request • unopened productProposed shelf-life start and expiry conventionLabeled storage range and relevant environmental factorsDistribution history and age at planned openingProduct identity, report revision, results and acceptance rationaleDuration and environmental wording pending review
Evidence request • opened and reclosed bottleFirst opening and elapsed-time conventionTemperature, closure state and relevant exposureHandling frequency and age when openedOpening log, storage log, sampling schedule and report locatorOpened-use limit unresolved
Evidence request • intermittent loadingOpening, unloading and reload eventsRefrigeration and instrument conditionsTransfer sequence and accumulated exposuresTime-stamped handling record linked to test observationsPermitted transfer workflow unresolved
Evidence request • continuously loaded reagentFirst load and defined onboard intervalActual reagent environment on instrumentUsage pattern and product age at loadingInstrument exposure records and corresponding performance dataOnboard limit unresolved
Evidence request • prepared reagent, where applicableMixing or reconstitutionPrepared-product storage and containerPreparation method and subsequent usePreparation record, performance observations and report revisionPrepared-product limit unresolved

WHO’s 2018 TGS–2 addresses in-use claims within its IVD prequalification guidance. Sections 9.1–9.3 ask for studies that simulate actual use as far as possible and support precisely defined in-use periods. Where the instructions state a range of use conditions, the guidance expects evidence across that range unless a documented rationale is provided. Section 9.1 describes good practice for assessing in-use stability at the beginning and end of shelf life and after simulated transport challenge. Section 9.2 asks manufacturers to consider freeze-thaw exposure during use, and section 9.3 expects evidence from routine-use testing for each claim when a product carries more than one in-use claim. Apply that guidance within its programme scope and justify the chosen conditions for the specific product. WHO TGS–2, printed pp. 27–28.

TGS–2 also explains why a single “in-use” label can hide several claims. Its definition note says that, for WHO’s purposes, in-use stability includes the number of times reagents can be removed, used and returned to storage without affecting kit performance. The note lists onboard, reconstitution and open-vial or bottle stability as examples, and it treats a calibration interval as another type of in-use life. That framing maps directly onto the separate rows in the evidence-request table. WHO TGS–2, definitions, printed p. 9.

An evidence request becomes actionable when it specifies both the missing field and the record needed to fill it. Ask for opening and loading records, component age, storage and exposure logs, sampling times, raw observations, acceptance criteria, deviations and the signed report identifier. Link the observations to the actual container being assessed. This proposed packet gives the reviewer a reproducible path from the instruction to the evidence.

  • Define the unit under review. Identify the bottle, cartridge or component, its lot, relevant configuration and document revision. Describe how the records distinguish a partly used unit from a replacement.

  • Define the claimed clock. Record the initiating event, time units and handling of removal or reloading. Ask the study owner to explain how the recorded schedule represents the proposed instruction.

  • Locate the performance observations. Connect each planned time point and exposure history to its results, exclusions and deviations. Keep the acceptance rationale beside the endpoint assessment.

  • Record the decision. Assign an owner to each unresolved condition and retain the reason for accepting, narrowing or requesting more evidence for the proposed wording.

Use the current stability method within its scope

CLSI EP25, second edition, was published on 26 April 2023 and replaced EP25-A. Its public scope covers reagent shelf-life and in-use claims, including qualitative products when an underlying continuous signal is available. The public change summary describes planning around allowable drift and removes a nonsignificant regression-slope test as sufficient justification for passing stability. It also describes observations at and beyond the claimed time. Consult the standard itself for its complete procedures. CLSI EP25 public scope and edition changes.

FDA’s recognition database lists EP25 second edition as recognition 7-318, entered 18 December 2023 in list 061, with complete-standard recognition. This establishes its position in FDA’s voluntary consensus standards framework. Assess use in another jurisdiction under that jurisdiction’s requirements. FDA recognition 7-318.

When preparing a new protocol, ask the analytical reviewer to document the endpoint, allowable change, sampling plan and interpretation before the study begins. Explain how the chosen measurements address the proposed claim and the intended use. Match the method edition in the protocol, report and evidence table. This proposed review step keeps a historical submission’s method citation traceable while allowing the new study to identify its own applicable methodology.

Reconcile the evidence with the released instructions

U.S. 21 CFR 809.10 also requires, for a reagent, a means of assuring that the product meets appropriate standards at the time of use, both as provided and after reconstitution or mixing. One permitted means is an expiration date based upon the stated storage instructions. The same section addresses reagent preparation instructions, specimen storage and the final reaction’s measurement window. Review each applicable statement against its own supporting evidence. The reagent’s usable period belongs alongside the conditions attached to it. 21 CFR 809.10(a)(6), (b)(5), (b)(7) and (b)(8).

Health Canada’s guidance adds a kit-level check. It bases the outer-container expiration date on the component with the shortest projected useful life and on studies showing that the device performs as intended until that date. It also expects expiration dates for opened components when they differ from the unopened product. A reconciliation should therefore confirm that each component’s opened-use statement and the kit expiry are consistent with each other and with the supporting reports. Health Canada, section 2.3.6.

Complete a final sentence-by-sentence reconciliation. For each proposed instruction, record the component, starting event, duration or date, environment, exposure sequence and supporting report. Check that the public wording includes any condition needed to interpret the claim correctly. Where a report leaves a material question unresolved, assign that question for resolution or bound the proposed wording to the supported use configuration.

Keep the released document revision in the claim record. When a closure, preparation step, instrument exposure or handling sequence changes, revisit the affected row and document the evidence assessment. The same table can support that review without importing an interval from another assay. Its useful output is a claim whose duration, conditions and initiating event can all be traced to the relevant product evidence.

For the neighboring pre-analytical task, the IVD specimen-stability guide addresses collection and transport evidence. For formulation and drying decisions, the lyophilized-reagent guide addresses the manufacturing configuration. Use those topics to identify which evidence file owns a question as the opened-reagent claim is assembled.

The examples here come from public documents. The HmX material is historical, and the FDA records describe the named submissions. Confirm current product instructions before making an operational use decision. Public summaries provide selected claim and study details. Completing a manufacturer’s record requires the current labeling and underlying reports for its proposed configuration.